Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was funded by Spanish Ministry of Science and Innovation (grant PID2020-117979RB-I00), the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF) (grant IMP/00019), and has also been funded by Consejeria de Salud y Familias, Junta de Andalucia (grants COVID-0012-2020, PS-2020-342 and IE19_259 FPS) and the postdoctoral contract of Carlos Loucera (PAIDI2020- DOC_00350) co-funded by the European Social Fund (FSE) 2014-2020.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Ethics Committee for the Coordination of Biomedical Research in Andalusia approved the study "Retrospective analysis of all COVID-19 patients in the entire Andalusian community and generation of a prognostic predictor that can be applied preventively in possible future outbreaks" (29th September, 2020, Acta 09/20) and the CEI from the University Hospitals Virgen Macarena and Virgen del Rocio approved the study "Medicina de precision en COVID-19 (PreMed-Covid19)" (22nd December 2020, acta CEI 21/2020), and waived informed consent for the secondary use of clinical data for research purposes in both cases.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes